MedPath

A Single Center, Open-label, Randomized Comparative Study to Evaluate the Effect of Aliskiren on Myocardial Perfusion Reserve and Coronary Flow Reserve in Hypertensive Patients with a history of Myocardial Infarctio

Not Applicable
Conditions
Hypertension
Registration Number
JPRN-UMIN000005511
Lead Sponsor
The University of Tokyo, department of cardiovascular medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1.Intolerance, anaphylaxis, or any history of hypersensitivity to aliskiren 2.Treated with high dose of RAS blockade 3.Initiation or change-a-dose/discontinuation of statin during 3 months prior to the registration, or planned change in a dose of statin during participating to this study 4.History of coronary artery bypass graft surgery 5.With any contraindication for MRI a)Pacemaker or ICD b)Implanted inner ear device c)Artificial tooth (regarded as an aberration if provided, however, that physician decided it doesn't matter) d)patient undergoing bronchial asthma treatment e)History of artificial vessel replacement for aortic aneurysm f)History of surgical clip therapy for brain aneurysm g)eGFR<50mL/min/1.73 m2 during 1 month prior to the MRI examination h)Judged as "Imcompetent for the study" by investigators i)Intolerance, anaphylaxis, or any history of hypersensitivity to Gd-DTPA 6.Uncontrolled severe diabetes ( HbA1c>9) 7.Unstable angina or a history of acute MI or stroke during 3 months prior to the registration 8.LVEF <30% 9.Severe liver dysfunction 10.Severe kidney disease 11.Pregnant, Women of Child Bearing Potential or using effective methods of contraception as defined by local Health Authority 12.Nursing (lactating) women 13.Hyperkalemia ( plasma K >5.5mEq/l) 14.eGFR<50mL/min/1.73 m2 during 1 month prior to the registration 15.Judged as "Imcompetent for the study" by investigators

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Myocardial Perfusion Reserve (MPR) and Ccoronary Flow Reserve (CFR) by magnetic resonance imaging (MRI) after 24 weeks
Secondary Outcome Measures
NameTimeMethod
1.Left ventricule mass, End-diastolic and end-systolic left ventricular volume (EDV and ESV) after 24 weeks 2.Change from baseline in systolic and diastolic blood pressure after 12 and 24 weeks 3.Biomarkers including BNP, hs-CRP, PRA and plasma aldosterone after 12 and 24 weeks
© Copyright 2025. All Rights Reserved by MedPath